Impacting Cancer

Nextech Invest, May 2016
Is this email not displaying correctly?
View it in your browser.

Dear Reader, 

We congratulate Blueprint Medicines for the completed Roche partnership and highlight the progress of other Nextech portfolio companies around the Annual Meeting of the American Association of Cancer Research (AACR). In the Editorial section, Alfred Scheidegger shares his experience from many years of investments in biotech on the cycles of innovation. Further, in the Nextech Insights section, Kristina Kakalacheva reviews the current market trends in cancer therapeutics with a focus on immuno-oncology. 

With kind regards, 
The Nextech Team

Portfolio Highlight

Blueprint Medicines and Roche Sign Partnership Deal

Blueprint Medicines (NASDAQ:BPMC) and Roche (SIX:ROG) announced a partnership in March 2016 to develop small molecule therapeutics for immuno-oncology. The deal involves an upfront payment of USD 45 million and consecutive milestone payments of up to USD 965 million, with USD 215 million in near term milestone payments prior to licensing, for a total of five drug candidates. Blueprint Medicines will retain US rights for up to two programs.

Read the press release

Editorial

Big Innovations Come in Cycles

Alfred Scheidegger, PhD, Founding Partner and CEO of Nextech Invest, shares his perspective on the cycles of innovation and the implications that scientific breakthroughs have for biotech investments.

Read the article

Portfolio News

Tracon Reports Progress on its Candidate TRC105

TRACON Pharmaceuticals (NASDAQ:TCON) has received Orphan Drug Status for TRC105 in Soft Tissue Sarcoma by both FDA and EMA. Furthermore, Tracon reported updated positive data on an ongoing complete response in a Choriocarcinoma patient and has initiated two additional clinical trials in lung and breast cancer.

Read the press release

Nextech Insights

Immuno-oncology Market Trends



Kristina Kakalacheva, PhD, Associate at Nextech Invest shares her insight into the oncology market. Immuno-oncology is not only revolutionizing treatment options but also drives partnering and M&A in the biotech sector.

Read the article.

Dr. William G. Kaelin, Professor at Harvard Medical School and Scientific Board member of Nextech Invest, was awarded the Princess Takamatsu Memorial Lectureship at the AACR Annual Meeting and will receive the Science of Oncology Award at ASCO. 

Read the press releases:
AACR ASCO.

Dr. Paul Workman, CEO of The Institute of Cancer Research and Scientific Board member of Nextech Invest, has been elected to the Royal Society Fellowship.

Read the press release

Jounce Therapeutics presented data highlighting advances from two programs in its immuno-oncology pipeline at the 2016 AACR Annual Meeting.

Read the press release

Peloton Therapeutics presented positive preclinical data on the first HIF-2α inhibitor in combination with immuno-oncology agents at the 2016 AACR Annual Meeting.

Read the press release.  

Impressum
Nextech Invest Ltd.
Turnerstrasse 26
8006 Zurich, Switzerland

Web: www.nextechinvest.com
E-Mail: info@nextechinvest.com